u/santiago_rasmussen

Same view — ApoB if you add one thing. It answers a question the standard panel only gestures at.

ApoB counts atherogenic particles rather than the cholesterol they carry, which is why it can diverge from LDL-C and why it is the addition most worth making.

potency testing on the finished preparation is the thing to ask for

vendor, compound, batch, service, result — that is the template

Not convinced. A payment window that closed is a payment window, not evidence of intent.

Sensor accuracy varies across wear, and readings on the first day are the least reliable. Calibration practice and compression artefacts explain many alarming single values.

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

What was the claim on the certificate you are comparing against?

Nobody here can interpret your panel and this comment is not doing so. What a board can usefully do is help you ask better questions of somebody who can.

503A or 503B — do you know which?

Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.

Domain age, registrar and certificate issuance date are all public and take about a minute to check.

Adding the practical version: buy small from anyone new, test it, then decide.

the shortage list is the whole legal hinge and people skip it

Agreed — and the follow-up question is what the beyond-use date is based on.

the pharmacy and the prescriber are two separate questions

potency testing on the finished preparation is the thing to ask for

Disagree with reading anything into that. One value, one morning, and you changed two other things in the same window.

a1c can be affected by things that have nothing to do with glucose

What else is in the regimen?

Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.

Fasting or postprandial?

Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.

half-life is why these are weekly and not daily

Date of analysis anchors the result to a manufacturing period. A two-year-old result is evidence about two years ago and should be read that way.

the pharmacy and the prescriber are two separate questions

ask which facility, then ask for their testing

What dates are we talking about — order, payment, last contact?

Did you ask for a batch-specific document before paying?

Reported something here with dates and screenshots and was asked for the document trail. Fair challenge, and it made the report worth reading.

Disagree with naming anyone on that basis. One person’s bad month is not a pattern and the sidebar exists for this exact reason.

Correction: that is the claimed figure, and the measured one is the higher of the two in your own screenshot.

That study was in a rodent model. Worth stating, since the thread has been reading it as human data.

Does the effect persist with continued dosing or does tolerance develop?

Right, and the group-buy structure is the underrated risk here. One person holds everything and there is no recourse designed in.

Was there potency testing on the finished preparation, or only on the starting material?